Sign up USA
Proactive Investors - Run By Investors For Investors

Allergan to buy body contouring company Zeltiq Aesthetics

Pharmaceutical group Allergan has announced the acquisition of Zeltiq Aesthetics for $2.475bn to gain access to its body contouring technology.
Allergan to buy body contouring company Zeltiq Aesthetics
Allergan is to buy Zeltiq Aesthetics

Botox maker Allergan (NYSE:AGN) has agreed to buy body contouring company Zeltiq Aesthetics for $2.475bn.

Dublin-based Allergan will pay $56.50 per Zeltiq share, a 14.4% premium to the group’s closing price on Friday.

The acquisition will give Allergan access to Zeliq’s body contouring technology, CoolSculpting System, which reduces stubborn fat cells that may not respond to diet or exercise.

The technology will compliment Allergan’s treatment, Kybella, which is used to reduce fat under the chin.

Allergan said body contouring presents a $4bn market opportunity worldwide and the purchase of Zeltiq will be immediately earnings accretive.

 "With CoolSculpting, our offerings to plastic surgeons, dermatologists and aesthetic practitioners will now extend to three of the largest and fastest-growing segments of their practices," chairman and chief executive Brent Saunders said.

The acquisition is subject to shareholder approval.

Since its $160bn merger with Pfizer collapsed in April, Allergan has been involved in a batch of deals including the acquisition of Acelity's LifeCell.

Allergan announced it was buying LifeCell, which produces products for breast reconstruction and soft tissue repair, in December and it is expected to boost the company’s earnings in coming years. 



Register here to be notified of future AGN Company articles
View full AGN profile View Profile

Allergan Timeline

Newswire
February 08 2017
Newswire
December 20 2016
Newswire
November 02 2016
Article
September 20 2016
Newswire
August 15 2016
Newswire
August 08 2016

Related Articles

pregnant woman sitting in park
June 13 2017
The £225,000 order is from HuanZhong Biotech, Concepta’s partner in China
shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
stem cell
June 12 2017
"With multiple value upside triggers ahead, including imminent maiden revenues from CellPlan, I very much look forward to the opportunities ahead" - CEO João Andrade
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use